Evaluation of MAGE-A Expression and Grade of Dysplasia for Predicting Malignant Progression of Oral Leukoplakia
Overview
Authors
Affiliations
The risk of the malignant transformation of oral leukoplakia (OLP) is difficult to predict by histopathology. Melanoma-associated antigen-A (MAGE-A) expression is restricted to malignant cells and may be useful for the more accurate estimation of the potential malignant transformation of pre-malignant lesions. The aim of the present study was to investigate whether the expression of MAGE-A can be used to predict the malignant transformation of OLP. Paraffin-embedded tissue samples of OLP from 74 patients followed-up for at least 5 years were included. A total of 24 progressing and 50 non-progressing OLP, 18 corresponding tumor and 30 healthy mucosa specimens were analysed for MAGE-A 1, 3, 4, 6 10 and 12 expression by nested real‑time RT-PCR and graded for dysplasia. In total, 46% of the progressing lesions expressed at least 1 out of the examined MAGE-A antigens, whereas no expression was detected in any of the non-progressing OLP and normal specimens. The correlation between malignant transformation and MAGE-A expression was statistically significant (p=0.00001). Furthermore, 42% of the progressing OLPs without dysplasia (D0) expressed at least 1 antigen. The correlation between the grade of dysplasia and MAGE-A staining in the malignant transformation group was not significant (p=0.08). The detection of at least 1 MAGE-A antigen may allow the identification of high-risk lesions that may progress into carcinoma with time. Therefore, the investigation of MAGE-A expression should be assessed in order to obtain a more accurate evaluation of the potential cancer risk of OLP.
Rushiti A, Castellani C, Cerrato A, Fedrigo M, Sbricoli L, Bressan E J Clin Med. 2024; 13(1).
PMID: 38202065 PMC: 10779469. DOI: 10.3390/jcm13010058.
Biomarkers of malignant transformation in oral leukoplakia: from bench to bedside.
Cai X, Zhang J, Zhang H, Li T J Zhejiang Univ Sci B. 2023; 24(10):868-882.
PMID: 37752089 PMC: 10522567. DOI: 10.1631/jzus.B2200589.
The Immune Cells in the Development of Oral Squamous Cell Carcinoma.
Caponio V, Zhurakivska K, Lo Muzio L, Troiano G, Cirillo N Cancers (Basel). 2023; 15(15).
PMID: 37568595 PMC: 10417065. DOI: 10.3390/cancers15153779.
Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.
Rangel R, Pickering C, Sikora A, Spiotto M Front Immunol. 2022; 13:840923.
PMID: 35154165 PMC: 8829003. DOI: 10.3389/fimmu.2022.840923.
Saldivia-Siracusa C, Gonzalez-Arriagada W Front Oral Health. 2022; 2:614045.
PMID: 35047990 PMC: 8757698. DOI: 10.3389/froh.2021.614045.